Omeprazole Articles

Mylan's 3rd-qtr revenues slump 17%

14 February 2005

Japan stock market week to January 24

31 January 2005

Biogenerics to command more than $12B by 2010

17 January 2005

Rx-to-OTC switching motives queried

17 January 2005

Mylan sees sales drop 15% for 2nd qtr

8 November 2004

Procter & Gamble's 1st-qtr EPS climbs 16%

1 November 2004

Schwarz' sales drop 17% for 3rd-qtr 2004

1 November 2004

AstraZeneca's EPS up 56%, sales rise 10%

1 November 2004

Mylan lowers 2nd-qtr earnings forecast

25 October 2004

Santarus' Zegerid available in the USA

11 October 2004

EXPO study reinforces supremacy claims for AstraZeneca's Nexium among PPIs

11 October 2004

Spain's Reig Jofre buys Antibioticos Farma's antibiotics brands

11 October 2004

French reimbursable pharma spending soars 8.7% in first-half 2004

13 September 2004

Santarus initiates pivotal trial of Zegerid

30 August 2004

Germany's Merck buys Pfizer's Scandinavian generic unit for $66.5M

30 August 2004

PPIs lead growth in $2.5B US OTC gastro market

23 August 2004

EU "set to find AstraZeneca guilty" of patent, other abuses to protect Losec from generics

16 August 2004

Schwarz' 1st-half 2004 sales tumble 49.9%

2 August 2004

Indian drug price study sees large trade margins

2 August 2004

Tokyo pharma stocks - week to july 12

19 July 2004

Mylan settles for $37.5M from Schwarz

5 July 2004

FDA clears Santarus' PPI Rapinex

21 June 2004

Generics slowed rising Rx costs in 2003: PBM

14 June 2004

French generics plan set to hit Rx patents

14 June 2004

Japan's Takeda exceeds initial sales forecasts in fiscal year to March

7 June 2004

Dr Reddy's sees full-year sales climb 11%

7 June 2004

Overseas sales boost Eisai's results

31 May 2004

Mylan's full-year EPS hits record

24 May 2004

Generics' major role in new French Rx policy

24 May 2004

Schwarz Pharma's sales dive 51.7%

10 May 2004

Merck KGaA's organic pharma sales up 4.3%

3 May 2004

S-P posts 1st-qtr loss of $73M as sales slide

3 May 2004

Merck & Co reports 5% drop in 1st-qtr income

3 May 2004

71% of pharma firms have fought generics with legal battles

26 April 2004

Axcan's Photobarr cleared in EU

5 April 2004

Yule Catto's profits up 39% in 2003

15 March 2004

Stock Commentary - Europe

1 March 2004

Merck KGaA

1 March 2004

US Rx drug sales up 11.5% in 2003, growth sustained by new products, says IMS

23 February 2004

Merck KGaA erases debt with sale of VWR; reports organic growth of 7% for 2003

23 February 2004

Dr Reddy's 3rd-qtr net profit falls 11%

9 February 2004

AstraZeneca forecasts sharp rise in earnings but shares slip on mediocre Crestor sales

9 February 2004

AstraZeneca 4th-qtr results lower, but in line with expectations

2 February 2004

Intron slump, charges lead to S-P loss

2 February 2004

Axcan's Photobarr on track for EU approval

5 January 2004

Lek defends omeprazole synthesis patent

30 November 2003

Schwarz wins US Losec generics battle

22 December 2003

Pharmaceutical marketing "in crisis," says report; new business models required

22 December 2003

AstraZeneca's Prilosec patents upheld in USA

22 December 2003

Near-term risks versus long-term upside at Germany's Altana assessed by MS

22 December 2003

Teva stays ahead of the pack with $3.4 billion Sicor acquisition

10 November 2003

Sales near flat at Merck KGaA in third qtr, generics grow as pipeline is restructured

3 November 2003

Merck KGaA reports strong third quarter

3 November 2003

Schwarz hit by more omeprazole generics

3 November 2003

AstraZeneca beats expectations as strong sales drive third-quarter growth

3 November 2003

AstraZeneca strikes $100M Abgenix deal

27 October 2003

AstraZeneca profits likely down in 3rd qtr?

27 October 2003

Biovail shares crash after motorway accident puts dent in revenues

13 October 2003

AstraZeneca's Crestor off to strong start in USA; overall performance on track

13 October 2003

P&G Prilosec claim on end of injunction

29 September 2003

P&G plans large Prilosec debut in USA

22 September 2003

Spain's new Rx reference price scheme "will strangle R&D and cut profits up to 25%"

22 September 2003

US insurers move on generics, OTCs

22 September 2003

AstraZeneca's cholesterol-lowerer Crestor finally gains FDA approval

18 August 2003

Stock Commentary - New York

18 August 2003

Stock Commentary - Europe

18 August 2003

Tokyo pharma stocks - week to August 11

18 August 2003

AstraZeneca and Schwarz strike back after shock Mylan omeprazole launch

18 August 2003

Stock Commentary - New York

11 August 2003

Axcan's Photofrin cleared for new use

11 August 2003

Mylan starts selling omeprazole in USA; sparks share collapse at Schwarz Pharma

11 August 2003

Euro Commission warns AstraZeneca of antitrust investigation on Losec

11 August 2003

Australian pharmacy deal "draining PBS"

4 August 2003

Schwarz still riding high on generic Prilosec

4 August 2003

AstraZeneca raises full-year earnings guidance on comforting 2nd-qtr results

4 August 2003

AstraZeneca raises full-year earnings guidance

28 July 2003

P&G targeting $400M from OTC Prilosec

21 July 2003

Santarus closes $55.1M placement

21 July 2003

Maine's Medicaid Rx preferred list launched

21 July 2003

US price rises for most-prescribed drugs to seniors are well ahead of

21 July 2003

Axcan's Photofrin gets US FDA nod for Barrett's esophagus

7 July 2003

AstraZeneca/P&G's Prilosec OTC cleared by FDA for frequent heartburn

30 June 2003

Pharma Resources says 2nd-qtr earnings above forecast

30 June 2003

UK Rx-OTC switch applications for statinsare imminent, AESGP hears

23 June 2003

US 2002 drug cost trends beat forecasts, says PBM, but generics, OTCs offer scope

16 June 2003

Mylan's ANDA for omeprazole delayed relese gets US OK

9 June 2003

Increasing US DTC advertising "raises concerns for prescribing," says study

2 June 2003

Celebrex GI safety study

26 May 2003

Crestor advisory panel raises fears of delay

26 May 2003

AstraZeneca's Iressa gets FDA approval for third-line use in NSCLC

12 May 2003

Profits down at AstraZeneca as Prilosec sales plummet, but Nexium turnover soars

5 May 2003

Schwarz lifts forecasts on strong generic sales

14 April 2003

Pliva closes deal to acquire Spain's Edigen

7 April 2003

2002 world pharma sales growth: slower but still healthy, says IMS

24 March 2003

World retail pharmacy sales for full-year 2002 slow to 7% growth, says IMS

3 March 2003

Schwarz forecasts two-fold earnings growth in 2003

3 March 2003

First launch, in Canada, for AstraZeneca's superstatin Crestor

24 February 2003

AstraZeneca files new data to US FDA on Crestor; possible approval in 2nd half

17 February 2003

High US co-pays "are driving PPI switches"

17 February 2003

Pliva to buy generics firm in Spain

17 February 2003

Showing 101-200 of 722 articles

Go to beginningPreviousNextGo to end